JP2008509218A - Ｈｃｖ複製の阻害剤 - Google Patents

Ｈｃｖ複製の阻害剤 Download PDF

Info

Publication number
JP2008509218A
JP2008509218A JP2007525623A JP2007525623A JP2008509218A JP 2008509218 A JP2008509218 A JP 2008509218A JP 2007525623 A JP2007525623 A JP 2007525623A JP 2007525623 A JP2007525623 A JP 2007525623A JP 2008509218 A JP2008509218 A JP 2008509218A
Authority
JP
Japan
Prior art keywords
compound
mmol
hcv
alkyl
cyclohexyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007525623A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008509218A5 (OSRAM
Inventor
トーマス・ダブリュー・フディマ
チェン・シャオファン
ヘ・フェン
ミン・ディン
カール・ピー・バーグストロム
ピヤセナ・ヘワワサム
スコット・ダブリュー・マーティン
ロバート・ジー・ジェントルズ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2008509218A publication Critical patent/JP2008509218A/ja
Publication of JP2008509218A5 publication Critical patent/JP2008509218A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2007525623A 2004-08-09 2005-07-15 Ｈｃｖ複製の阻害剤 Withdrawn JP2008509218A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US60893204P 2004-08-09 2004-08-09
US66055505P 2005-03-11 2005-03-11
US11/181,639 US7153848B2 (en) 2004-08-09 2005-07-14 Inhibitors of HCV replication
PCT/US2005/025234 WO2006020082A1 (en) 2004-08-09 2005-07-15 Inhibitors of hcv replication

Publications (2)

Publication Number Publication Date
JP2008509218A true JP2008509218A (ja) 2008-03-27
JP2008509218A5 JP2008509218A5 (OSRAM) 2008-09-18

Family

ID=35385782

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007525623A Withdrawn JP2008509218A (ja) 2004-08-09 2005-07-15 Ｈｃｖ複製の阻害剤

Country Status (11)

Country Link
US (1) US7153848B2 (OSRAM)
EP (1) EP1776368A1 (OSRAM)
JP (1) JP2008509218A (OSRAM)
KR (1) KR20070049635A (OSRAM)
AU (1) AU2005274959A1 (OSRAM)
BR (1) BRPI0514176A (OSRAM)
CA (1) CA2576421A1 (OSRAM)
IL (1) IL180738A0 (OSRAM)
MX (1) MX2007001683A (OSRAM)
NO (1) NO20070751L (OSRAM)
WO (1) WO2006020082A1 (OSRAM)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011517673A (ja) * 2008-03-27 2011-06-16 ブリストル−マイヤーズ スクイブ カンパニー 芳香族ヘテロ環縮合インドロベンザジアゼピンｈｃｖｎｓ５ｂ阻害剤
JP2012513434A (ja) * 2008-12-22 2012-06-14 エフ．ホフマン−ラ ロシュ アーゲー 複素環式抗ウイルス化合物
JP2015528008A (ja) * 2012-07-18 2015-09-24 ブリストル−マイヤーズ・スクイブ・ホールディングス・アイルランドＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｈｏｌｄｉｎｇｓ Ｉｒｅｌａｎｄ （４ｂＳ，５ａＲ）−１２−シクロヘキシル−Ｎ−（Ｎ，Ｎ−ジメチルスルファモイル）−３−メトキシ−５ａ−（（１Ｒ，５Ｓ）−３−メチル−３，８−ジアザビシクロ［３．２．１］オクタン−８−カルボニル）−４ｂ，５，５ａ，６−テトラヒドロベンゾ［３，４］シクロプロパ［５，６］アゼピノ［１，２−Ａ］インドール−９−カルボキサミドを製造するための新規な方法および中間体

Families Citing this family (140)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6080216A (en) * 1998-04-22 2000-06-27 3M Innovative Properties Company Layered alumina-based abrasive grit, abrasive products, and methods
EP1688420A4 (en) * 2003-11-19 2008-10-22 Japan Tobacco Inc 5-5 LOW-CONDENSED HETEROCYCLIC COMPOUND AND THEIR USE AS HCV POLYMERASE INHIBITOR
US20070049593A1 (en) * 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
US7795247B2 (en) * 2004-10-26 2010-09-14 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Tetracyclic indole derivatives as antiviral agents
AU2005298403A1 (en) * 2004-10-26 2006-05-04 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Tetracyclic indole derivatives as antiviral agents
US7659263B2 (en) 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
AU2006242475B2 (en) 2005-05-02 2011-07-07 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
JP4705984B2 (ja) 2005-08-01 2011-06-22 メルク・シャープ・エンド・ドーム・コーポレイション Ｈｃｖｎｓ３プロテアーゼ阻害剤としての大環状ペプチド
GB0518390D0 (en) * 2005-09-09 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
US7399758B2 (en) * 2005-09-12 2008-07-15 Meanwell Nicholas A Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7473688B2 (en) 2005-09-13 2009-01-06 Bristol-Myers Squibb Company Indolobenzazepine HCV NS5B inhibitors
WO2007092000A1 (en) * 2006-02-06 2007-08-16 Bristol-Myers Squibb Company Inhibitors of hcv replication
US7456165B2 (en) 2006-02-08 2008-11-25 Bristol-Myers Squibb Company HCV NS5B inhibitors
GB0608928D0 (en) * 2006-05-08 2006-06-14 Angeletti P Ist Richerche Bio Therapeutic agents
GB0609492D0 (en) 2006-05-15 2006-06-21 Angeletti P Ist Richerche Bio Therapeutic agents
US7521443B2 (en) * 2006-05-17 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
CN101443336B (zh) * 2006-05-17 2012-07-04 百时美施贵宝公司 环丙基稠合的[吲哚]并[苯并氮杂*]hcv ns5b抑制剂
US7456166B2 (en) * 2006-05-17 2008-11-25 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521441B2 (en) * 2006-05-22 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521442B2 (en) 2006-05-25 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
CN101490054B (zh) * 2006-05-25 2012-05-16 百时美施贵宝公司 环丙基稠合的吲哚并苯并氮杂*hcv ns5b抑制剂
US7452876B2 (en) 2006-06-08 2008-11-18 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
GB0612423D0 (en) 2006-06-23 2006-08-02 Angeletti P Ist Richerche Bio Therapeutic agents
EP2374812B1 (en) 2006-07-13 2015-04-15 Achillion Pharmaceuticals, Inc. 4-amino-4-oxobutanoyl Peptides as Inhibitors of Viral Replication
KR20090029827A (ko) * 2006-07-20 2009-03-23 제네랩스 테크놀로지스, 인코포레이티드 폴리사이클릭 바이러스 억제제
EP2079480B1 (en) 2006-10-24 2013-06-05 Merck Sharp & Dohme Corp. Hcv ns3 protease inhibitors
AU2007309544B2 (en) 2006-10-24 2012-05-31 Msd Italia S.R.L. HCV NS3 protease inhibitors
AU2007309546A1 (en) 2006-10-24 2008-05-02 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. HCV NS3 protease inhibitors
AU2007318165B2 (en) 2006-10-27 2011-11-17 Msd Italia S.R.L. HCV NS3 protease inhibitors
EP2083844B1 (en) 2006-10-27 2013-11-27 Merck Sharp & Dohme Corp. Hcv ns3 protease inhibitors
EP2121707B1 (en) * 2006-12-20 2012-12-05 Istituto di Ricerche di Biologia Molecolare P. Angeletti S.R.L. Antiviral indoles
GB0625349D0 (en) 2006-12-20 2007-01-31 Angeletti P Ist Richerche Bio Therapeutic compounds
GB0625345D0 (en) 2006-12-20 2007-01-31 Angeletti P Ist Richerche Bio Therapeutic compounds
MX2009006877A (es) 2006-12-22 2009-09-28 Schering Corp Derivados indolicos con anillo unido en las posiciones 5,6 y metodos de uso de los mismos.
CA2673254C (en) 2006-12-22 2013-09-10 Schering Corporation 4,5-ring annulated indole derivatives for treating or preventing of hcv and related viral infections
RU2009127855A (ru) * 2006-12-22 2011-01-27 Шеринг Корпорейшн (US) 4,5 циклоаннелированные производные индола для лечения или предотвращения вируса гепатита с (hcv) и родственных вирусных инфекций
US7541351B2 (en) * 2007-01-11 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7541352B2 (en) * 2007-02-02 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7517872B2 (en) * 2007-02-22 2009-04-14 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
CA2679377A1 (en) * 2007-02-26 2008-09-04 Achillion Pharmaceuticals, Inc. Tertiary amine substituted peptides useful as inhibitors of hcv replication
AU2008219622A1 (en) 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Methods for the treatment of liver diseases using specified matrix metalloproteinase (MMP) inhibitors
US7998951B2 (en) * 2007-03-05 2011-08-16 Bristol-Myers Squibb Company HCV NS5B inhibitors
JP5211078B2 (ja) * 2007-03-13 2013-06-12 ブリストル−マイヤーズ スクイブ カンパニー シクロプロピル縮合インドロベンズアゼピンｈｃｖｎｓ５ｂ阻害剤
US7521444B2 (en) * 2007-03-14 2009-04-21 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7541353B2 (en) * 2007-03-14 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7547690B2 (en) * 2007-03-14 2009-06-16 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US7538102B2 (en) 2007-03-14 2009-05-26 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US7538103B2 (en) * 2007-03-15 2009-05-26 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
EP2494991A1 (en) 2007-05-04 2012-09-05 Vertex Pharmaceuticals Incorporated Combination therapy for the treatment of HCV infection
CN101801982A (zh) * 2007-07-17 2010-08-11 P.安杰莱蒂分子生物学研究所 用于治疗丙型肝炎感染的大环吲哚衍生物
US8927569B2 (en) 2007-07-19 2015-01-06 Merck Sharp & Dohme Corp. Macrocyclic compounds as antiviral agents
US7652004B2 (en) * 2007-08-09 2010-01-26 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8143243B2 (en) * 2007-08-09 2012-03-27 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7642251B2 (en) 2007-08-09 2010-01-05 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
CN101821252A (zh) 2007-08-29 2010-09-01 先灵公司 取代的吲哚衍生物及其使用方法
MX2010002316A (es) * 2007-08-29 2010-03-22 Schering Corp Derivados tetraciclicos de indol y su uso para el tratamiento o prevencion de infecciones virales.
PE20090995A1 (es) 2007-08-29 2009-08-03 Schering Corp Derivados indolicos 2,3-sustituidos como inhibidores del virus de la hepatitis c (vhc)
PE20090994A1 (es) 2007-08-29 2009-08-03 Schering Corp Derivados de azaindol 2,3-sustituidos como agentes antivirales
WO2009064848A1 (en) 2007-11-16 2009-05-22 Schering Corporation 3-heterocyclic substituted indole derivatives and methods of use thereof
WO2009064852A1 (en) 2007-11-16 2009-05-22 Schering Corporation 3-aminosulfonyl substituted indole derivatives and methods of use thereof
US8124601B2 (en) 2007-11-21 2012-02-28 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US8129367B2 (en) * 2007-11-21 2012-03-06 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
EA201000948A1 (ru) 2007-12-19 2011-02-28 Бёрингер Ингельхайм Интернациональ Гмбх Ингибиторы вирусной полимеразы
AU2008339917B2 (en) 2007-12-24 2013-02-07 Tibotec Pharmaceuticals Macrocyclic indoles as hepatitis C virus inhibitors
US8147818B2 (en) * 2008-02-13 2012-04-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2280978B1 (en) * 2008-03-27 2013-04-24 Bristol-Myers Squibb Company Pyrrolidine fused indolobenzadiazepine hcv ns5b inhibitors
US8178523B2 (en) * 2008-03-27 2012-05-15 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8138171B2 (en) * 2008-03-27 2012-03-20 Bristol-Myers Squibb Company Dioxolane and dioxolanone fused indolobenzadiazepine HCV NS5B inhibitors
EP2271345B1 (en) 2008-04-28 2015-05-20 Merck Sharp & Dohme Corp. Hcv ns3 protease inhibitors
US8133884B2 (en) * 2008-05-06 2012-03-13 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
CN102159579B (zh) 2008-06-13 2015-03-25 默沙东公司 三环吲哚衍生物及其使用方法
TWI454476B (zh) * 2008-07-08 2014-10-01 Tibotec Pharm Ltd 用作ｃ型肝炎病毒抑制劑之巨環吲哚衍生物
EP2540349B1 (en) 2008-07-22 2014-02-12 Merck Sharp & Dohme Corp. Pharmaceutical compositions comprising a macrocyclic quinoxaline compound which is an hcv ns3 protease inhibitor
KR20110042116A (ko) 2008-08-11 2011-04-22 글락소스미스클라인 엘엘씨 알레르기성, 염증성 및 감염성 질환의 치료에서 사용하기 위한 푸린 유도체
UA103195C2 (uk) 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
CN102176911B (zh) 2008-08-11 2014-12-10 葛兰素史密丝克莱恩有限责任公司 新的腺嘌呤衍生物
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
JP5669749B2 (ja) * 2008-12-10 2015-02-12 アキリオン ファーマシューティカルズ，インコーポレーテッド ウイルス複製の阻害剤である４−アミノ−４−オキソブタノイルペプチド環状類似体
JP5723783B2 (ja) * 2008-12-10 2015-05-27 アキリオン ファーマシューティカルズ，インコーポレーテッド ウイルス複製の阻害剤としての新しい４−アミノ−４−オキソブタノイルペプチド
US8551973B2 (en) 2008-12-23 2013-10-08 Gilead Pharmasset Llc Nucleoside analogs
NZ593647A (en) 2008-12-23 2013-08-30 Gilead Pharmasset Llc Synthesis of purine nucleosides
SG172359A1 (en) 2008-12-23 2011-07-28 Pharmasset Inc Nucleoside phosphoramidates
MX2011007195A (es) 2009-01-07 2013-07-12 Scynexis Inc Derivado de ciclosporina para el uso en el tratamiento de infección de virus de hepatitis c (vhc) y virus de inmunodeficiencia humana (vih).
EP2396329B1 (en) * 2009-02-11 2014-10-29 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis c
US8143244B2 (en) * 2009-02-26 2012-03-27 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US20190127365A1 (en) 2017-11-01 2019-05-02 Merck Sharp & Dohme Corp. Inhibitors of hepatitis c virus replication
JP5913091B2 (ja) 2009-03-27 2016-04-27 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｃ型肝炎ウイルス複製の阻害剤
WO2010114896A1 (en) * 2009-03-31 2010-10-07 Arqule, Inc. Substituted indolo-pyridinone compounds
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI598358B (zh) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
US8828930B2 (en) 2009-07-30 2014-09-09 Merck Sharp & Dohme Corp. Hepatitis C virus NS3 protease inhibitors
WO2011098451A1 (en) 2010-02-10 2011-08-18 Glaxosmithkline Llc Purine derivatives and their pharmaceutical uses
BR112012018904A2 (pt) 2010-02-10 2020-09-01 Glaxosmithkline Llc composto, adjuvante de vacina, composições imunogênica, de vacina e farmacêutica, e uso de um composto"
CN102918049A (zh) * 2010-03-09 2013-02-06 默沙东公司 稠合三环甲硅烷基化合物及其用于治疗病毒性疾病的方法
JP2013527145A (ja) 2010-03-31 2013-06-27 ギリード・ファーマセット・エルエルシー リン含有活性化剤の立体選択的合成
TW201136945A (en) 2010-03-31 2011-11-01 Pharmasset Inc Purine nucleoside phosphoramidate
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
BR112012032889A2 (pt) 2010-06-24 2015-09-15 Janssen R & D Ireland preparação do ácido 13-ciclo-hexil-3-metóxi-6-[metil-(2-{2-[metil-(sulfamoil)-amino]-etóxi}-etil)-carbamoil]-7h-indol-[2,1-a]-[2]-benzazepina-10-carboxílico
JP2013540122A (ja) 2010-09-29 2013-10-31 メルク・シャープ・エンド・ドーム・コーポレイション 縮合四環式化合物誘導体およびウィルス疾患治療のためのそれの使用方法
PT3042910T (pt) 2010-11-30 2019-04-16 Gilead Pharmasset Llc 2'-espiro-nucleósidos para utilização na terapia da hepatite c
EP2658858A4 (en) 2010-12-30 2014-06-25 Enanta Pharm Inc MACROCYCLIC INHIBITORS OF HEPATITIS C SERINE PROTEASE PHENANTHRIDINE
MX2013007677A (es) 2010-12-30 2013-07-30 Abbvie Inc Inhibidores macrociclicos de serina proteasa de hepatitis.
WO2012122716A1 (en) 2011-03-17 2012-09-20 Merck Sharp & Dohme Corp. Tetracyclic xanthene derivatives and methods of use thereof for treatment of viral diseases
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
CA2840242C (en) 2011-09-16 2019-03-26 Gilead Sciences, Inc. Methods for treating hcv
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
GB2515942A (en) 2011-10-21 2015-01-07 Abbvie Inc Combination treatment (e.g. with ABT-072 or ABT-333) of DAAs for use in treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
PT107894A (pt) 2011-10-21 2014-10-31 Abbvie Inc Métodos para o tratamento de hcv compreendendo pelo menos dois agentes antivirais de actuação directa, ribavirina, mas não interferão.
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
US10202392B2 (en) 2012-04-26 2019-02-12 Francis Xavier Tavares Synthesis of lactams
WO2014110687A1 (en) 2013-01-16 2014-07-24 Merck Sharp & Dohme Corp. Thiazolyl-substitued tetracyclic compounds and methods of use thereof for treatment of viral diseases
KR20200060782A (ko) 2013-01-31 2020-06-01 길리애드 파마셋 엘엘씨 두 항바이러스 화합물의 병용 제형물
WO2014121417A1 (en) * 2013-02-07 2014-08-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
WO2014121416A1 (en) * 2013-02-07 2014-08-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
WO2014121418A1 (en) 2013-02-07 2014-08-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
AU2014227849A1 (en) 2013-03-15 2015-10-01 Achillion Pharmaceuticals, Inc. Sovaprevir polymorphs and methods of manufacture thereof
WO2014145600A1 (en) 2013-03-15 2014-09-18 Achillion Pharmaceuticals, Inc. Ach-0142684 sodium salt polymorphs, composition including the same, and method of manufacture thereof
WO2014145507A1 (en) 2013-03-15 2014-09-18 Achillion Pharmaceuticals, Inc. A process for making a 4-amino-4-oxobutanoyl peptide cyclic analogue, an inhibitor of viral replication, and intermediates thereof
EP3650014B1 (en) 2013-08-27 2021-10-06 Gilead Pharmasset LLC Combination formulation of two antiviral compounds
WO2015061407A1 (en) * 2013-10-24 2015-04-30 Francis Xavier Tavares Process for synthesis of lactams
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
WO2015124591A1 (en) 2014-02-20 2015-08-27 Glaxosmithkline Intellectual Property (No.2) Limited Pyrrolo[3,2] pyrimidine derivatives as inducers of human interferon
US10584125B2 (en) 2014-11-13 2020-03-10 Glaxosmithkline Biologicals Sa Adenine derivatives which are useful in the treatment of allergic diseases or other inflammatory conditions
RU2020113165A (ru) 2015-12-03 2020-06-09 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Циклические пуриновые динуклеотиды в качестве модуляторов sting
JP2019510802A (ja) 2016-04-07 2019-04-18 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ タンパク質調節物質として有用な複素環アミド
CN113549110B (zh) 2016-04-07 2024-08-16 葛兰素史密斯克莱知识产权发展有限公司 用作蛋白质调节剂的杂环酰胺
US11192914B2 (en) 2016-04-28 2021-12-07 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
CA3063288A1 (en) 2017-05-12 2018-11-15 Mavalon Therapeutics Limited Substituted heterocyclic compounds as allosteric modulators of group ii metabotropic glutamate receptors
JP2020536106A (ja) 2017-10-05 2020-12-10 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ｈｉｖの処置に有用なインターフェロン遺伝子の刺激物質（ｓｔｉｎｇ）の調節物質
BR112020006780A2 (pt) 2017-10-05 2020-10-06 Glaxosmithkline Intellectual Property Development Limited moduladores do estimulador de genes do interferon (sting)
GB201807924D0 (en) 2018-05-16 2018-06-27 Ctxt Pty Ltd Compounds
JP2022533390A (ja) 2019-05-16 2022-07-22 スティングセラ インコーポレイテッド オキソアクリジニル酢酸誘導体および使用方法
EP3969452A1 (en) 2019-05-16 2022-03-23 Stingthera, Inc. Benzo[b][1,8]naphthyridine acetic acid derivatives and methods of use
GB201910304D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
GB201910305D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
CN114981265B (zh) 2019-12-18 2025-01-03 Ctxt私人有限公司 化合物
US12274700B1 (en) 2020-10-30 2025-04-15 Accencio LLC Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK13752001A3 (sk) 1999-12-27 2002-07-02 Japan Tobacco, Inc. Zlúčeniny s fúzovanými kruhmi a ich použitie ako liečiv
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
CA2448737C (en) 2001-07-20 2010-06-01 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
EP2335700A1 (en) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
US7223785B2 (en) 2003-01-22 2007-05-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US7098231B2 (en) 2003-01-22 2006-08-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
GB0307891D0 (en) 2003-04-04 2003-05-14 Angeletti P Ist Richerche Bio Chemical compounds,compositions and uses
KR101164070B1 (ko) 2003-05-09 2012-07-12 베링거 인겔하임 인터내셔날 게엠베하 Ｃ형 간염 바이러스 ｎｓ5ｂ 폴리머라제 억제제 결합 포켓
CN1829709A (zh) 2003-08-01 2006-09-06 健亚生物科技公司 对抗黄病毒的双环咪唑衍生物
WO2005014543A1 (ja) 2003-08-06 2005-02-17 Japan Tobacco Inc. 縮合環化合物及びそのｈｃｖポリメラーゼ阻害剤としての利用
GB0323845D0 (en) 2003-10-10 2003-11-12 Angeletti P Ist Richerche Bio Chemical compounds,compositions and uses
US20050119318A1 (en) 2003-10-31 2005-06-02 Hudyma Thomas W. Inhibitors of HCV replication
IN2012DN04853A (OSRAM) 2004-02-20 2015-09-25 Boehringer Ingelheim Int
DE602005013922D1 (de) 2004-02-24 2009-05-28 Japan Tobacco Inc Kondensierte heterotetracyclische verbindungen und deren verwendung als hcv-polymerase-inhibitor

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011517673A (ja) * 2008-03-27 2011-06-16 ブリストル−マイヤーズ スクイブ カンパニー 芳香族ヘテロ環縮合インドロベンザジアゼピンｈｃｖｎｓ５ｂ阻害剤
JP2012513434A (ja) * 2008-12-22 2012-06-14 エフ．ホフマン−ラ ロシュ アーゲー 複素環式抗ウイルス化合物
JP2015528008A (ja) * 2012-07-18 2015-09-24 ブリストル−マイヤーズ・スクイブ・ホールディングス・アイルランドＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｈｏｌｄｉｎｇｓ Ｉｒｅｌａｎｄ （４ｂＳ，５ａＲ）−１２−シクロヘキシル−Ｎ−（Ｎ，Ｎ−ジメチルスルファモイル）−３−メトキシ−５ａ−（（１Ｒ，５Ｓ）−３−メチル−３，８−ジアザビシクロ［３．２．１］オクタン−８−カルボニル）−４ｂ，５，５ａ，６−テトラヒドロベンゾ［３，４］シクロプロパ［５，６］アゼピノ［１，２−Ａ］インドール−９−カルボキサミドを製造するための新規な方法および中間体

Also Published As

Publication number Publication date
AU2005274959A1 (en) 2006-02-23
US20060046983A1 (en) 2006-03-02
BRPI0514176A (pt) 2008-06-03
CA2576421A1 (en) 2006-02-23
NO20070751L (no) 2007-05-07
WO2006020082A1 (en) 2006-02-23
IL180738A0 (en) 2007-06-03
KR20070049635A (ko) 2007-05-11
MX2007001683A (es) 2007-04-12
EP1776368A1 (en) 2007-04-25
US7153848B2 (en) 2006-12-26

Similar Documents

Publication Publication Date Title
JP2008509218A (ja) Ｈｃｖ複製の阻害剤
US7348425B2 (en) Inhibitors of HCV replication
JP5147731B2 (ja) Ｈｃｖｎｓ５ｂ阻害剤
JP5232178B2 (ja) Ｃ型肝炎の治療のための化合物
JP5284952B2 (ja) シクロプロピル縮合インドロベンゾアゼピンｈｃｖｎｓ５ｂ阻害剤
US7485633B2 (en) Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
JP5301473B2 (ja) Ｃ型肝炎の治療のための化合物
JP5416710B2 (ja) シクロプロピル縮合インドロベンズアゼピンｈｃｖｎｓ５ｂ阻害剤
AU2007246850B2 (en) Pentacyclic indole derivatives as antiviral agents
JP5343011B2 (ja) Ｃ型肝炎の治療のための化合物
JP5209647B2 (ja) Ｃ型肝炎の治療のための化合物
JP5306366B2 (ja) Ｃ型肝炎治療のための化合物
WO2007033175A1 (en) Indolobenzazepine hcv ns5b inhibitors
WO2007092000A1 (en) Inhibitors of hcv replication
JP2010521483A (ja) シクロプロピル縮合インドロベンゾアゼピンｈｃｖインヒビター
JP2012519173A (ja) シクロプロピル縮合インドロベンズアゼピンｈｃｖｎｓ５ｂ阻害剤
JP5211078B2 (ja) シクロプロピル縮合インドロベンズアゼピンｈｃｖｎｓ５ｂ阻害剤
JPWO2005051949A1 (ja) 新規縮合イミダゾール誘導体
JP2011515484A (ja) ピロリジン縮合インドロベンザジアゼピンｈｃｖｎｓ５ｂ阻害剤
EP2231668A1 (en) Condensed pentacyclic derivatives for use in the treatment of flaviviridae infections

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080710

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080804

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20091207